Plasma S100A9 was measured in 58 MPN patients, including 22 ET, 17 PV, and 19 MF (comprising 4-ETMF, one 4-PVMF, and 11 PMF) and 10 controls. This evidence concerns the gene S100A9 and myeloproliferative disorder.